Acquisitions
Acquisitions completed from the 2023 financial year are distributed among the group’s business areas as follows:
| Acquisitions | Time | Net Sales, SEKm* | Number of employees* | Business area |
|---|---|---|---|---|
| Emmat Medical Ltd, Great Britain | September, 2023 | 28 | 4 | Medtech |
| 28 | 4 | |||
| Acquisitions after the end of the interim period | Time | Net Sales, SEKm* | Number of employees* | Business area |
| BonsaiLab, Spain | July, 2024 | 90 | 13 | Labtech |
| 90 | 13 | |||
| * Refers to conditions at the time of acquisition on a full-year basis. | ||||
Revaluation of liabilities for contingent considerations related to previous acquisitions in the Medtech Business Area has resulted in an income of SEK 7m. During the interim period, these have been reversed and reported in other operating income. Contingent consideration amounting to SEK 41m has been paid during the interim period regarding BioConnect, Funksjonsutstyr and O'Flynn, which were acquired in previous years.
Latest updated: 7/13/2024 3:22:41 PM by jamilah.wass@add.life